IRIS

1.5 Abstract in Rivista: [1767] Home page tipologia

Sfoglia
Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 441 a 460 di 1.767
Titolo Data di pubblicazione Autore(i) File
Dose-dense chemotherapy (CT) with modified dose-dense TCF regimen (TCF-dd) in metastatic gastric cancer (MGC): Update of a phase II study 1-gen-2010 Dalla Chiesa, M; Poli, R; Tomasello, G; Lazzarelli, S; Buti, S; Brighenti, M; Negri, F; Curti, A; Auzzani, A; Passalacqua, R
High efficacy of sequential chemotherapy (CT) with dose-dense modified TCF regimen (TCF-DD) followed by CT with oxaliplatin, folinic acid (FA), 5-fluorouracil (5-FU) and irinotecan (COFFI) in metastatic gastric cancer (MGC) 1-gen-2008 Dalla Chiesa, M; Tomasello, G; Buti, S; Negri, F; Brighenti, M; Lazzarelli, S; Auzzani, A; Curti, A; Martinotti, M; Passalacqua, R
Phase II study of chemotherapy with oxaliplatin (Ox), irinotecan (Ir), levo-folinic acid (L-FA) and 5-fluorouracil (5-FU) (COFFI) in metastatic gastric cancer (MGC) 1-gen-2005 Chiesa, Md; Buti, S; Tomasello, G; Negri, F; Donati, G; Cattaneo, M; Gnocchi, N; Bozzetti, R; Buononato, M; Passalacqua, R
Role of chemotherapy in metastatic renal cell cancer (MRC) resistant to treatment with IL-2 and IFN alpha 1-gen-2006 Brighenti, M; Buti, S; Chiesa, Md; Tomasello, G; Buzio, C; Bongiovanni, C; Alberici, F; Passalacqua, R
Bevacizumab (B) plus low-doses immunotherapy (IT), plus chemotherapy (CT) (BIC), in metastatic renal cell cancer (mRCC): antitumor effects and variations of T-regulatory cells (Treg) and other T lymphocytes subsets. A study of the Italian Oncology Group for Clinical Research (GOIRC) 1-gen-2008 Buti, S; Lazzarelli, S; Rivoltini, L; Castelli, C; Camisaschi, C; Simonelli, C; Lo Re, G; Mattioli, R; Mazza, G; Brighenti, M; Passalacqua, R
Dose-dense chemotherapy (CT) with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A phase II study 1-gen-2007 Chiesa, Md; Tomasello, G; Buti, S; Negri, F; Buononato, M; Longarini, R; Lazzarelli, S; Brighenti, M; Passalacqua, R
Impact of intermittent (I) first-line docetaxel (D)-based chemotherapy on quality of life (QL) of patients (pts) with castration-resistant prostate cancer (CRPC): Results of a phase II randomized trial 1-gen-2013 Caffo, O; Sava, T; Basso, U; Buti, S; Lo Re, G; Sacco, C; Lodde, M; Facchini, G; Zustovich, F; Perin, A; Russo, L; Veccia, A; Galligioni, E
Dose-dense chemotherapy (CT) with modified dose-dense TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): update of a phase II study 1-gen-2010 Dalla Chiesa, M; Poli, R; Tomasello, G; Lazzarelli, S; Brighenti, M; Negri, F; Curti, A; Auzzani, A; Buti, S; Liguigli, W; Passalacqua, R
Integration of tissue and circulating parameters identifies a favorable immune profile in NSCLC patients treated with nivolumab 1-gen-2018 Mazzaschi, G; Facchinetti, F; Madeddu, D; Buti, S; Gelsomino, F; Ardizzoni, A; Aversa, F; Missale, G; Quaini, F; Tiseo, M
High efficacy of sequential chemotherapy (CT) with dose-dense modified TCF regimen (TCF-DD) followed by CT with Oxaliplatin, Folinic Acid (FA), 5-Fluorouracil (5-FU) and Irinotecan (COFFI) in metastatic gastric cancer (MGC) 1-gen-2008 Dalla Chiesa, M; Tomasello, G; Buti, S; Negri, F; Brighenti, M; Lazzarelli, S; Auzzani, A; Curti, A; Martinotti, M; Passalacqua, R
A new modified sunitinib schedule for metastatic renal cell cancer (mRCC): A pilot study 1-gen-2012 Buti, S; Donini, M; Lazzarelli, S; Brighenti, M; Passalacqua, R
Safety and efficacy of Cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP) 1-gen-2017 Procopio, G; Prisciandaro, M; Iacovelli, R; Mancini, M; Fornarini, G; Facchini, G; Carteni, G; Napolitano, M; Sternberg, Cn; Caserta, C; Bregni, M; Massari, F; Buti, S; Biasco, E; De Giorgi, U; Zustovich, F; Ratta, R; Ortega, C; Tortora, G; Verzoni, E
Dose-dense chemotherapy with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A feasibility study 1-gen-2006 Dalla Chiesa, M; Tomasello, G; Buti, S; Negri, F; Buononato, M; Lazzarelli, S; Brighenti, M; Donati, G; Cattaneo, M; Passalacqua, R
Gefitinib plus interleukin-2 (IL-2) in previously treated patients with advanced non-small-cell lung cancer (NSCLC) 1-gen-2005 Buti, S; Chiesa, Md; Tomasello, G; Negri, F; Machiavelli, A; Bosio, G; Stifani, I; Betti, M; Buononato, M; Passalacqua, R
LOH as “the missing instability” potentially underlying the tumor immunogenicity: on the trails of a correlation between fractional allelic loss and response to nivolumab in renal cancer 1-gen-2017 Bersanelli, M; Gnetti, L; Azzoni, C; Bottarelli, L; Gasparro, D; Leonardi, F; Silini, Em; Buti, S
Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs) 1-gen-2015 Santini, D; Santoni, M; Conti, A; Procopio, G; Verzoni, E; Galli, L; Di Lorenzo, G; De Giorgi, U; De Lisi, D; Nicodemo, M; Maruzzo, M; Massari, F; Buti, S; Biasco, E; Ricotta, R; Porta, C; Vincenzi, B; Marchetti, P; Cascinu, S; Tonini, G
Adjuvant low-dose interleukin-2 (IL2) plus interferone-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC) 1-gen-2007 Passalacqua, R; Buzio, C; Buti, S; Labianca, R; Porta, C; Boni, C; Rondini, E; Camisa, R; Sabbatini, R; Artioli, F; Caminiti, C
Relationship between enzalutamide activity and previous antiandrogen withdrawal syndrome (AWS) in patients with metastatic castration-resistant prostate cancer (MCRPC) 1-gen-2015 Alesini, D; Sisani, M; Altavilla, A; Procopio, G; Hamzaj, A; Grillone, F; Massari, F; Marrocolo, F; Zaniboni, A; Mattioli, R; Buti, S; Battaglia, M; Caffo, O; De Angelis, V; Bracarda, S
Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient's counselling preliminary analysis of the INVIDIa study 1-gen-2017 Bersanelli, M; Castrignanò, P; Gambale, E; Cortellini, A; Tiseo, M; Natoli, C; Ficorella, C; Panni, S; Rossetti, S; Papa, A; Mazzoni, F; Facchini, G; De Giorgi, U; Procopio, G; Atzori, F; Sava, T; De Luca, E; Maestri, A; Massari, F; Buti, S
Negative prognostic factors and resulting clinical outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) included in the Italian nivolumab expanded access program (EAP) 1-gen-2017 Bracarda, S; Galli, L; Maruzzo, M; Lo Re, G; Buti, S; Favaretto, A; Costanzo, Fd; Sacco, C; Merlano, M; Mucciarini, C; Zafarana, E; Romito, S; Maestri, A; Giorgio, Cg; Ionta, Mt; Turci, D; De Giorgi, U; Procopio, G; Cortesi, E; Porta, C
Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 441 a 460 di 1.767
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile

Scopri
Tipologia
  • 1 Articolo su rivista1767
Autore
  • DI MARIO, Francesco242
  • BUTI, Sebastiano150
  • GIULIANI, Nicola126
  • ALBERTINI, Roberto87
  • SEBASTIANI, MARCO85
  • SCARPIGNATO, Carmelo75
  • AGNETTI, Aldo66
  • PARRINO, Liborio66
  • MUSOLINO, Antonino61
  • CARANO, Nicola60
Data di pubblicazione
  • 2020 - 2025192
  • 2010 - 2019832
  • 2000 - 2009517
  • 1990 - 1999174
  • 1980 - 198951
  • 1979 - 19791
Editore
  • ELSEVIER25
  • SAGE PUBLICATIONS LTD17
  • DIKE GIURIDICA15
  • Elsevier13
  • ASCO pubs11
  • ELSEVIER IRELAND LTD7
  • ASCO6
  • ELSEVIER SCIENCE INC5
  • SAGE5
  • SPRINGERNATURE4
Rivista
  • DIGESTIVE AND LIVER DISEASE101
  • GASTROENTEROLOGY100
  • ANNALS OF ONCOLOGY93
  • BLOOD89
  • JOURNAL OF CLINICAL ONCOLOGY58
  • HAEMATOLOGICA56
  • NEUROLOGICAL SCIENCES47
  • UNITED EUROPEAN GASTROENTEROLOGY ...46
  • ANNALS OF THE RHEUMATIC DISEASES36
  • REUMATISMO26
Keyword
  • Helicobacter pylori10
  • sclerosi sistemica6
  • Bioengineering5
  • Gastroenterology5
  • HCV5
  • UV5
  • GERD4
  • Lungs4
  • anodal stimulation3
  • beat-to-beat variability of cardi...3
Lingua
  • eng926
  • ita177
  • fre1
Accesso al fulltext
  • no fulltext1735
  • reserved26
  • open6